undamentalytics Newsletter

Militello John: insider trades

Officer at Rocket Pharmaceuticals, Inc. No open-market purchases and 17 sales not made under a pre-set plan, reported from February 22, 2023 to February 18, 2026.

What happened after Militello John’s sales?

After their sales, the shares moved −64.4% against the index over 12 months on average (a negative figure means selling was the right call); 86% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

Trade by trade

Militello John: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 0 — — — — — — Not enough years
Purchases, 6 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 14 −24.2% −24.6% 79% 3 — — Not enough years
Sales, 12 months after the report 14 −64.4% −82.7% 86% 3 — — Not enough years
Sales, 12 months after the trade 14 −67.2% −84.9% 79% 3 — — Not enough years

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Rocket Pharmaceuticals, Inc. RCKT See Remarks017February 22, 2023February 18, 2026

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
February 18, 2026February 13, 2026 RCKT Sale $12,333 not yetnot yetnot yet
October 16, 2025October 14, 2025 RCKT Sale $114,612 not yetnot yetnot yet
August 18, 2025August 14, 2025 RCKT Sale $21,270 not yetnot yetnot yet
February 25, 2025February 21, 2025 RCKT Sale $28,957 −73.1%−64.1%−75.3%
November 25, 2024November 21, 2024 RCKT Sale $15,973 −35.2%−92.2%−90.8%
November 4, 2024October 31, 2024 RCKT Sale $15,250 −44.4%−99.3%−100.4%
August 20, 2024August 16, 2024 RCKT Sale $19,684 −39.8%−98.3%−96.8%
July 24, 2024July 22, 2024 RCKT Sale $18,692 −39.7%−107.8%−102.5%
May 20, 2024May 16, 2024 RCKT Sale $25,195 −16.3%−82.3%−84.3%
April 24, 2024April 22, 2024 RCKT Sale $19,051 +6.1%−78.6%−79.7%
March 25, 2024March 21, 2024 RCKT Sale $69,969 −25.3%−79.9%−82.1%
March 4, 2024February 29, 2024 RCKT Sale $298,500 −23.8%−83.2%−85.4%
February 21, 2024February 16, 2024 RCKT Sale $96,622 −27.3%−86.3%−87.5%
January 23, 2024January 22, 2024 RCKT Sale $17,354 −19.6%−86.6%−88.2%
July 24, 2023July 20, 2023 RCKT Sale $10,904 +4.1%+29.0%+6.4%
April 25, 2023April 21, 2023 RCKT Sale $43,678 −15.5%−2.1%+3.2%
February 22, 2023February 17, 2023 RCKT Sale $23,711 +11.4%+30.0%+22.5%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Militello John traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.